Royalty Report: Wound Care, Medical, Drugs – Collection: 7364

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 15

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 15

Primary Industries

  • Wound Care
  • Medical
  • Drugs
  • Supply
  • Pharmaceuticals
  • Pain
  • Coating
  • Therapeutic
  • Consumer Goods
  • Retail & Leisure
  • Textiles
  • Health & Fitness
  • Personal Care Products
  • Internet
  • Software
  • Game
  • Online Games-MMOG

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7364

License Grant
The Licensor and the Licensee of an India entered into a Patent and Technology License Agreement to License the Nimbus® intellectual property.

Under the Agreement, the Licensor grants the Licensee exclusive rights to use the Nimbus intellectual property in hydrophilic polyurethane foam for wound care applications and for securing intravenous tubings and catheters on products sold in Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Ukraine, Uzbekistan, Russia and their territories and possessions.

License Property
The antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS® received de Novo FDA clearance in June 2009 and has been commercialized in traditional wound care applications.  Additional applications under development include advanced wound dressings, medical adhesives, and catheters.

NIMBUS® is based on non-toxic, long chain polymers with high charge density that provide superior efficacy via a physical action on microbes. By destroying bacteria at the cellular level, NIMBUS® eliminates the risk of developing drug resistance. The technology is highly effective against a multitude of bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus (VRE), two of the most significant antibiotic-resistant organisms responsible for hospital infections.

The Marks and Trademarks of Licensor include without limitation Quick-Med Technologies, QMT, Quick-Med, NIMBUS, and accompanying logos and trade dress, including the QMT Cross Official Logo

Patent
Intrinsically Bactericidal Absorbent Dressing and Method of Fabrication – IN/PCT/2001/00776/MUM
Method of Attaching An Antimicrobial Cationic Electrolyte To The Surface of A Substrate – PCT/US2006/32955
Polyelectrolyte Complex for Imparting Antimicrobial Properties to a Substrate – PCT/US2009/051163

Field of Use
Field means hydrophilic polyurethane foam in various shapes and sizes, used solely for wound care applications as primary or secondary dressings and for securing intravenous tubings and catheters.

IPSCIO Record ID: 7246

License Grant
Licensor hereby grants to Licensee and its Affiliates during the Term an exclusive, royalty-bearing right and license, with the right to grant sublicenses, under the Licensor Intellectual Property to make, use, sell, and offer for sale Products within the Field in the Territory.

Licensor has now agreed to license the Patent Rights and Technology to Licensee on an exclusive basis in the Field and Territory

License Property
Licensor owns or controls certain Patent Rights and Technology relating to its proprietary Nimbus® technology and has the right to grant licenses under such Patent Rights and Technology.

U.S. Patents
Intrinsically Bactericidal Absorbent Dressing and Method of Fabrication
U.S. 7,045,673 (May 16, 2006)

Materials with Covalently Bonded, Nonleachable Polymeric Antimicrobial Surfaces
U.S. 7,708,694 (May 4, 2010)

Method of Attaching an Antimicrobial Cationic Electrolyte to the Surface of a Substrate
U.S. 7,790,217 (September 7, 2010)
U.S. 8,092,854 (January 10, 2012)

International Patents
Intrinsically Bactericidal Absorbent Dressing and Method of Fabrication
Australia 773,532 (September 9, 2004)
Canada 2,353,436 (January 8, 2008)
China ZL 99814229.8 (January 12, 2005)
Korea 100689020 (February 23, 2007)
Mexico 248078 (August 15, 2007)
Russia 004160 (February 26, 2004)

Method of Attaching an Antimicrobial Cationic Polyelectrolyte to the Surface of a Substrate
Mexico 297242 (March 20, 2012)
Antimicrobial Cationic Electrolyte Coating
South Africa 2008/01601 (May 27, 2009)

Antimicrobial Cationic Polyelectrolyte Coatings
Australia 2006283043 (June 16, 2011)

Pending U.S. Patent Applications
Antimicrobial Bandage Material Comprising Superabsorbent and Non-Superabsorbent Layers US 2010-0211035 (May 3, 2010)

Polyelectrolyte Complex for Imparting Antimicrobial Properties to a Substrate US 2010-0291169 (July 2, 2010)

Pending International Patent Applications
Intrinsically Bactericidal Absorbent Dressing and Method of Fabrication
Europe 1156766

Method of Attaching an Antimicrobial Cationic Polyelectrolyte to the Surface of a Substrate
Brazil PI0617099-4

Antimicrobial Cationic Polyelectrolyte Coating
Canada 2620203
China 101291743

Method of Attaching an Antimicrobial Cationic Polyelectrolyte to the Surface of a Substrate
Europe 1937418
Japan 2008-528126

Polyelectrolyte Complex for Imparting Antimicrobial Properties to a Substrate
Australia 2009270715
Brazil P10911004-6
Canada 2731072
China 200980132939.0
Europe 2 320 958

Field of Use
Field means Traditional Wound Care Products sold to the institutional market, and products sold to the veterinary and dental institutional market except for (i) mouth cotton and (ii) the Biosara 100% rayon products for sale to the sport medicine and institutional market. For the avoidance of doubt, the Field excludes sales to the OTC/retail market.

IPSCIO Record ID: 369414

License Grant
The Parties amend the Agreement to modify the products and materials that are subject to the Agreement; extend the Agreement subject to certain conditions; and to make other material changes to the original Agreement.
License Property
Patents shall mean U.S. 7,045,673 – Intrinsically bactericidal absorbent dressing and method of fabrication

Products include the following
1. Conforming gauze bandage used as a secondary dressing to hold primary dressing in place  either 100% cotton or a blend of rayon and PET
2. Gauze sponges, gauze bandage rolls, gauze packing strips  100% cotton
3. 100% cotton, Rayon/PET blend or cotton/polyester blend nonwoven sponges
4. Dressings constructed of 100% cotton or cotton/rayon blend sandwiched between layers of PET (Mylar) or PA (Nylon) either with or without an adhesive border

Materials shall mean Polydiallyldimethyl ammonium chloride with specified substrate materials. (100% cotton and blends of rayon and PET)

Trademark shall include without limitation “Quick-Med Technologies” “QMT”, “Quick-Med”, “NIMBUS”, and accompanying logos and trade dress, including the QMT Cross Official Logo, which is subject to modification by Licensor from time to time.

The patent for company's proprietary NIMBUS(R) polymeric antimicrobial technology is applicable to a variety of base materials including woven and nonwoven fabrics.
The broad range of materials covered under the provisions of the patent include those that are composed of natural fibers, such as cotton and wool, as well as synthetics such as polyurethane, polyester, nylon and polypropylene. The applications included in the allowed claims are for a full spectrum of products such as medical devices including wound and burn dressings and blood transfer and storage products, surgical drapes and gowns, bedding, industrial and military protective wear and consumer apparel plus hygienic products such as wipes, diapers and feminine care.

Field of Use
NIMBUS is the first non-leaching antimicrobial available in a wound dressing. The dressings serve as a barrier to infection, kill germs absorbed into the dressing, and do not interfere with tissue healing. The NIMBUS active agent maintains effectiveness even in the presence of large amounts of proteinaceous exudates.

Field means the field of conforming gauze, gauze sponges, gauze bandage rolls, gauze packing strips, rayon/PET, cotton or cotton/polyester blend nonwoven sponges, and dressings constructed of 100% cotton or cotton/rayon blend sandwiched between layers of PET (Mylar) or PA (nylon) non-adherent perforated film used solely for wound care and sold to the institutional market not for resale as more specifically described in agreement.  The Field specifically excludes products provided to, developed for, or sold to the general, over-the-counter consumer market and, subject to the non-exclusive rights granted to DERMA pursuant hereof, the United States government, including, without limitation, the Department of Defense and/or agencies and military services thereof.

Licensor Policy on Use of Licensor Marks, Trademarks and Official Logo All Licensed Products that include Licensor technology, and related product packaging, advertising, promotional and marketing materials, shall display Licensor’s Official Logo in a size and prominence in accordance with industry standards. Use of Licensor’s Official Logo (the Logo) shall maintain the integrity of the Logo’s design. The color used is Burgundy, Black and White.  Licensor’s Marks, including but not limited to its name and Official Logo shall be displayed in a size and prominence at least equal to similar marks, names and logos for similar products or methods on any product, packaging, documentation, advertising, promotional, marketing, and related materials in accordance with industry standards.  The elements of the Licensor trade dress cannot be separated without the prior permission of Licensor.

IPSCIO Record ID: 26208

License Grant
The University gave the Company exclusive sub-license rights to the use of its patents and patent applications.
License Property
The Company holds exclusive worldwide rights for the manufacturing, marketing, and distribution of its Nimbus(TM) and topical MultiStat(TM) technologies.

Patent applications relate to the new projects treatment of mustard gas, Nimbus treatment of lumber, and antimicrobial and antiproteolytic wound dressing and method. Nimbus (Nimbus or 'Nimbus technology'), a family of polymers that are bio-engineered to have antimicrobial, super-absorbent, and other properties that can be used in a wide range of applications, such as wound dressings and apparel.

MultiStat (MutltiStat),is a family of patented matrix metalloproteinase inhibitors (MMPIs) that are believe to have significant benefit in the maintenance, healing and repair of skin and eyes. Independent laboratories as well as in-house research show that MultiStat is effective in medical (wound care) and consumer (cosmetic) applications. MultiStat is currently being sold as a performance ingredient to several cosmetics companies.

Field of Use
Licensee is seeking to use our Nimbus technology in (a) advanced wound care products and other medical devices; and (b) consumer products, including apparel and personal care. Licensee believes that the size and growth characteristics of the antimicrobial market represent an attractive opportunity for the Nimbus technology.  

The Licensee's four core technologies are Novel Intrinsically Micro-Bonded Utility Substrate (NIMBUS®), a family of advanced polymers bio-engineered to have antimicrobial, hemostatic, and other properties that can be used in a wide range of applications; Stay Fresh® is a unique chemical formulation for textiles with a durable antimicrobial agent effective against an array of bacteria even after numerous laundering cycles; NimbuDerm® is a novel copolymer for application as a persistent hand sanitizer with long lasting protection against germs; and MultiStat, a family of advanced patented methods and compounds shown to be effective in skin therapy applications.

IPSCIO Record ID: 138

License Grant
The Licensor agrees to grant an exclusive License to such Patent (7.045,673) Rights relating to its proprietary antimicrobial NIMBUS® technology in the Field and Exclusive territory and a non-exclusive License to such Patent Rights and Technology in the Field in the Non-exclusive territory on the terms and conditions of this Agreement.
License Property
Products
1. Conforming gauze bandage used as a secondary dressing to hold primary dressing in place either 100% cotton or a blend of rayon and PET

2. Gauze sponges, gauze bandage rolls, gauze packing strips 100% cotton

3. Oil emulsion acetate 100% acetate

4.

Unna boot 100% cotton

Field of Use
NIMBUS is the first non-leaching antimicrobial available in a wound dressing. The dressings serve as a barrier to infection, kill germs absorbed into the dressing, and do not interfere with tissue healing. The NIMBUS active agent maintains effectiveness even in the presence of large amounts of proteinaceous exudates.

Field means the field of conforming gauze, oil-emulsion acetate, gauze sponges, gauze bandage rolls, gauze packing strips and Unna Boot dressings used solely for wound care and sold to the institutional market not for resale.

IPSCIO Record ID: 7172

License Grant
The Licensor granted a temporary small reduction in the royalty rates on certain cotton-based BIOGUARD products for a six month period beginning from January 1 to June 30, 2011.  The royalty rate for these cotton-based products resumed effectively on July 1, 2011.
License Property
Novel Intrinsically Micro-Bonded Utility Substrate (NIMBUS®), is a family of advanced polymers bio-engineered to have antimicrobial, hemostatic, and other properties that can be used in a wide range of applications, including wound care, catheters, tubing, films, and coatings.
Field of Use
The Licensee, launched the commercial sale of BIOGUARD® an advanced wound care product employing the Licensor's NIMBUS technology.

IPSCIO Record ID: 4192

License Grant
Licensor hereby grants to the Licensee an exclusive right and license to use the Fiber to manufacture, use, offer for sale, sell, and otherwise commercialize the Licensed Products in the Territory and to use the Trademarks in connection with the manufacture, sale, use, and distribution of Licensed Products in the Territory. No other right or license is granted by the Licensor to the Licensee, either express or implied, with respect to any other trademark, trade name, service mark, or other intellectual property right owned or possessed by, or licensed to, the Licensor. The Licensee shall not use the Fiber or the Trademarks in any manner not specifically authorized by this Agreement.

Licensee and Licensor also entered into a Collateral Assignment of 510(k) Rights, pursuant to which Licensee granted Licensor a security interest in the FDA Clearance.

License Property
The Licensed Property is the Licensor's silver coated fibers marketed under the trademarks X-Static® and SilverSeal® in the Licensee's manufacture, sale, use and distribution of Hydrogel Wound Dressing identified in 510(k) K040019 and Hydrocolloid Wound Dressing identified in 510(k) K033900.

These two products utilize X-STATIC®, Licensor’s proprietary silver-based antimicrobial fiber used for advanced wound care, infection control and odor elimination.  The licensed dressings, a hydrocolloid with X-STATIC® and a hydrogel with X-STATIC® that utilizes hydrogels, have already received their 510(k) clearance from the U.S. Food and Drug Administration.

Field of Use
X-STATIC® enhances the effectiveness of medical devices used for wound care, burn care, skin care and infection prevention. Benefits are believed to include continuous, sustained release of silver cations for broad spectrum antimicrobial protection; demonstration of rapid bactericidal activity against a broad range of pathogens in pharmacodynamic in vitro models; no flaking or shedding of elemental silver; high versatility, allowing dressings to be used for multiple wound applications; no staining of patient, wound bed or clinician; and smoother skin application and greater patient comfort.

The Licensee further agreed to purchase all Fibers for use in the Licensed Products from the Licensor and all fabrics and yarns containing the Fibers from mills that have entered into licensing arrangements with the Licensor for the manufacture of fabrics or yarns containing the Fibers.

The Licensee also agreed to use commercially reasonable efforts to market the Licensed Products and make and maintain adequate arrangements for the manufacture, distribution, advertising and promotion of the Licensed Products.

IPSCIO Record ID: 256319

License Grant
The University grants a worldwide right and license to make, have made, use, lease, sell, and sublicense the Pre-issuance Products and Licensed Products under the Patent Rights, and to practice and sublicense the Pre-issuance Processes and Licensed Processes to the full end of the term(s) for which Patent Rights are granted unless sooner terminated as hereinafter provided.
License Property
The Invention will mean a wound treatment technology, Method and Apparatus to Enhance Closure and Health of Open Wounds.

The patents are Wound Dressing and Treatment Method, Fluidic Connection System and Method, and, Fastening System and Method.

Field of Use
Licensee is a global medical technology company in advanced wound care and therapeutic surfaces.

IPSCIO Record ID: 180166

License Grant
The Israeli Licensor grants to the Israeli Licensee an exclusive, perpetual, worldwide license under the Licensed Information to research, develop, make, have made, manufacture, use, sell, offer for sale, sublicense, import, export, commercialize and distribute, and grant sublicenses with respect to any and/or all of the foregoing, Licensed Products.

Licensee shall be entitled to grant Sublicenses to third parties at Licensee’s discretion, provided Licensor’s rights are not adversely affected by such Sublicenses, and provided that Licensee shall guarantee performance of all financial liabilities hereunder by any Sublicensee.

License Property
Licensor represents that it owns all rights in and to the patent application known as PCT/IL2009/000946, which Patent relates to a wound dressing and methods of preparation and use thereof for promoting healing of wound bed.  The wound dressing is advantageous for application to a debrided wound bed. The wound dressing comprises an open conduit polymeric foam matrix, and a hydrophilic polymer which is disposed in dry form on the inner surfaces of the conduits within the matrix.

The present invention provides a wound dressing for application onto a wound bed following debridement, and methods of use thereof to create an interface layer microenvironment (ILM) conducive to wound healing.

Field of Use
This agreement related to the medical industry.

IPSCIO Record ID: 362680

License Grant
The Licensee is party to an exclusive license with Licensor for the development and commercialization of Dexmedetomidine for use in the treatment of pain in humans in any dosage form for transdermal, transmucosal (including sublingual and intranasal), topical, enteral or pulmonary (inhalational) delivery, but specifically excluding delivery vehicles for administration by injection or infusion, worldwide, except for Europe, Turkey and the CIS (currently includes Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan), referred to herein as the Territory.
License Property
Dexmedetomidine means the compound known as “dexmedetomidine” or 4-((1S-1-(2,3-Dimethylphenyl)ethyl)-1H-imidazole including hydrates, stereoisomers, salts, and mixtures thereof.

Dex (dexmedetomidine) is a selective alpha-2 adrenergic agonist that has demonstrated sedative, analgesic and anxiolytic properties. Dex has an extensive commercial history of safe injectable use.

Field of Use
Field of use is for the treatment of pain in humans.

IPSCIO Record ID: 5848

License Grant
The Company, on behalf of a wholly-owned subsidiary to be formed, entered into a manufacturing agreement with an entity affiliated with a director of the Company. The agreement grants the Company the exclusive rights to manufacture patented hydrophilic urethane foam products, polyurethane gels and moisture managed foam footwear inserts and to distribute, along with the Licensor, these products in North America.  The manufacturing agreement also provides for a supply agreement between the two companies.
License Property
Licensor is the owner of substantial technology, issued and pending U.S. and foreign patents, Know-How (as such term is defined below) and proprietary information (collectively, the 'Technology') for the production and manufacture
of hydrophilic urethane foam products and polyurethane gels, components and materials (the 'Products').

Trademarks Silverwear(TM) and Dryz Gelz(TM)

Patents

1.   US Pat No. 5,976,616 – Polyurethane Foam Materials With Skin Conditioning Additives

2.   US Pat No. 6,566,576 B1 – Hydrocolloid Foam Medical Dressings and Method Of Making The Same

3.   US Patent No.  6,706,775  –  Polyurethane Foam Products  with Controlled release of Agents and Additives

4.   US Patent  Application – Elastic bandage  incorporating a Hydrophilic foam dressing

5.   US Patent  Application –  Elastomeric  Matrix with  Fragrance  Comprising a Synthetic Vapor Permeable Film To Control Release

Dryz Patents

6. US PAT NO. 5,763,335

7. US PAT NO. 6,025,287

Field of Use
Products manufactured under this agreement are being sold for use in cosmetic, medical, and household markets including the foot-care market under the brand name DRYZ, a registered trademark. In December 2005, the subsidiary was formed as a wholly-owned subsidiary of the Company to control this activity.

IPSCIO Record ID: 4355

License Grant
The Licensor hereby grants to the Licensee, an exclusive, worldwide royalty-bearing, assignable, transferable, irrevocable License with the right to grant sublicenses of the Licensee Products, and to make or to have made for the Licensee’s use, import, or offer for sale, or any combination thereof, Licensee Products within the territory.
License Property
Licensed Technology means any intellectual property, invention, know-how, trade secrets, technical information, research and development information, test results, and data that comprise or form part of the certain invention concerning SilverlonOTC Wound Care

Licensed Patents
U.S. 7,230,153 C2
U.S. 7,291,762 B2
U.S. 7,989,674 B2
U.S. 8,093,444 B2
U.S. 8,118,791

Field of Use
The licensing agreement enables the Licensee to develop, market and sell OTC wound care products based on Silverlon’s proprietary silver coating technology, which provides superior performance for wound treatment. The technology, with its permanently plated metallic surface, reduces the occurrence of surgical site infections.

IPSCIO Record ID: 2678

License Grant
The Canadian University granted the Licensee an exclusive, worldwide License to use and subLicense certain defined Technology comprised primarily of three broad patents for antimicrobial peptides and related methods of use and any improvements within a specified field of use and including the right to manufacture, distribute and sell products utilizing the Technology.

The Licensee shall have the right to grant sublicenses to Affiliated Companies and other third parties with respect to the Technology and any Improvements solely within the Field of Use. The Licensee will furnish the University with a copy of each sublicense granted within 30 days after execution.

License Property
98-005 USA 09/143,124 Anti-Endotoxic , Antimicrobial Hancock, REW 8/28/98 Cationic Peptides and Methods of Use Gough, M Therefor Patrzykat, A Woods, D Jia X

98-005 PCT WO 00/12528 Anti-Endotoxic , Antimicrobial As above 8/27/99 Cationic Peptides and Methods of Use Therefor

98-006 USA 6,172,185 Antimicrobial Cationic Peptide Hancock, REW Issued Derivatives of Bactenecin Wu, M 1/9/01

00-005 USA 09/604,864 Antimicrobial Peptides and Methods of Hancock, REW 7/27/00 Use Thereof Zhang, L.

Field of Use
'Field of Use' all fields of use, save and except the SynGene Field of Use.

'SynGene Field of Use' the use of antimicrobial peptides for the creation and development of disease resistant transgenic plants.

The Licensee's four core technologies are  Novel Intrinsically Micro-Bonded Utility Substrate (NIMBUS®), a family of advanced polymers bio-engineered to have antimicrobial, hemostatic, and other properties that can be used in a wide range of applications; Stay Fresh® is a unique chemical formulation for textiles with a durable antimicrobial agent effective against an array of bacteria even after numerous laundering cycles; NimbuDerm® is a novel copolymer for application as a persistent hand sanitizer with long lasting protection against germs; and MultiStat, a family of advanced patented methods and compounds shown to be effective in skin therapy applications.

IPSCIO Record ID: 275061

License Grant
Licensee acquired an exclusive world-wide license to market, sell and further develop antimicrobial products  utilizing certain Licensor patents and pending patent applications.  A director and indirect principal shareholder of Licensee is also a director of Licensor, and indirectly a significant shareholder of Licensor, and through the potential exercise of warrants a majority shareholder.
License Property
Currently, the products covered by the License Agreement are BIAKOSâ„¢ Antimicrobial Wound Gel, and FDA cleared BIAKOSâ„¢ Antimicrobial Skin and Wound Cleanser.
Field of Use
The field of use is for the prevention and treatment of microbes on the human body.  The agreement pertains to the wound care industry.

IPSCIO Record ID: 635

License Grant
The Russian Licensee and Korean Licensor entered into a this non-transferable, exclusive and royalty-bearing License and distribution agreement within the territory of shall mean the territory of the Former Soviet Republics  Armenia, Azerbaijan, Belorussia, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan.
License Property
Licensor has developed and owns all rights in computer programs of online game Requiem Online.  Requiem is a massively multiplayer online role-playing game.

Unless explicitly approved in writing by the Licensor, the Licensee shall have no right to sublicense.

Field of Use
This Exclusive Requiem Online License and Distribution Agreement is with respect to Intellectual Property rights which shall mean all patents, designs, utility models, copyrights, know-how, trade secrets, trademarks, service mark, trade dress and any other intellectual property rights in or related to the Game or Technical Information.  Licensee shall provide Game services only by way of the PC on-line method (excluding mobile access) using the Servers.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.